Stereotactic ablative radiotherapy delivered by helical tomotherapy for extracraneal oligometastasis  by Matute, R. et al.
S350 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S337–S354
infrared cameras of the ExacTrac® system for automatice treatment position. IGRT is performed before each treatment ﬁeld. The
6D robotic couch allows translational and rotational corrections. Sliding Windows IMRT treatment is administered with multiple
coplanar beams.
Results. FromNovember/2008 to January/2013,wehave treated 17patientswith 22 spinemetastasis, all the patients received single
18Gy, GTV is contoured as the entire body of the vertebra and/or the affected transverse and spinous processes, PTV is obtained
by expanding 2–3mm GTV. OARs dose constrains are based on RTOG-0631 protocol. The location of the vertebral metastasis
was: cervical 5, thoracic 9, lumbar 8; none of the patients have had prior radiotherapy on the treatment ﬁeld. 8 patients (47.05%)
have pain VAS≥5. With a median follow up of 17.6 months (0.5–43.5), 20 tumors had local control after treatment. No grade III
toxicity was found, total pain control was achieved in 70% of the patients, with a pain reduction in 90% (median months from
the treatment 3.8 weeks).
Conclusions. Vertebral radiosurgery is safe an accurate for spinal metastases, achieving fast and good results in pain and tumoral
control.
http://dx.doi.org/10.1016/j.rpor.2013.03.554
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Purpose. To present preliminary experience in the treatment of CNS metastases with radiosurgery, using multiple non-coplanar
arcs with RapidArc®.
Methods. From June to December 2012 ten patients were included (7 patients with single mts, 2 with two mts, and one pts with
4 mts). Mean age was 65 yo. (57–79). Primary tumour was: lung 6, breast 2, colon 1, prostate 1. ECOG distribution: 0:1; 1:5; 2:3;
3:1. Only two patients have evidence of metastases outside of CNS with minimal burden. Immobilization was performed with
thermoplastic mask and CT simulation with slices of 1.5mm. Treatment consists of 4–5 non-coplanar arcs (VMAT) with different
table rotation (0, 60, 30, 330 and 360◦). Prescription dose ranged from 12 to 18Gy. Dosimetric objectives were: 99% of PTV and 100%
of GTV must received 100% of prescription dose. Quality of treatment planning was evaluated with Paddick index, homogeneity
index and gradient index. Geometric veriﬁcation was made with cone beam CT. Median PTV was 6.6 cm3 (0.4–36 cm3).
Results. Dosimetric results: Quality index were superior compared to other techniques (cones, tomotherapy, and cyberknife).
Total treatment time (median): 29 + 8min. Clinical results: Acute toxicity: there were two case of mild hemiparesia, and one
case of headache. Local control: only one patient showed local progression. Regional control: two patients developed other
CNS metastases and were rescued with another radiosurgery, and one patient developed multiple CNS metastases requiring
holocraneal irradiation. Three patients were deceased because of disease progression. Seven patients were alive after a mean
follow-up of 17 weeks.
Conclusions. Single fraction radiosurgery with RapidArc® with multiple non-coplanar arcs showed high accuracy and quality.
Toxicity was mild and early results are comparable with other radiosurgery techniques.
http://dx.doi.org/10.1016/j.rpor.2013.03.555
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Purpose. Several recent studies have shown that a subset of patients with metastatic cancer in limited organs may beneﬁt from
metastasis-directed therapy.
Aim. We present a series on patients treated with stereotactic tomotherapy (HT), and assess the efﬁcacy and toxicity of this new
technology in the treatment of extracraneal oligometastasis.
Materials and methods. From August 2006 through July 2011, 42 consecutive patients (median age 69 years) with 1–3 metastatic
cancer sites receivedHT to all known cancer sites (lung, n=28; liver, n=12; adrenal, n=2). Twenty-seven patients (64%) had a single
lesion, 12 patients (29%) 2 lesions, and 3 patients (7%) 3 lesions. Acute toxicities were scored using the Common Terminology
Criteria version 3.0.
Results. A total of 60 lesions were treated with hypofractionated HT (median dose 39Gy [range 36–72.5]; median dose per fraction
12Gy [range, 5–20]). With a median follow-up period of 15 months (range 2–57), 1- and 2-year overall survival (OS) was 84%
and 63%, respectively; and 1- and 2-year local control (LC) was 92% and 86%, respectively. Regarding treatment-related acute
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Grade≥2 toxicity, there were 3 and 1 patient with pneumonitis Grades 2 and 3, respectively; one patient had Grade 2 diarrhea;
and one patient experienced Grade 3 lower gastrointestinal hemorrhage. On univariate analysis, having a longer time from the
primary tumor diagnosis date to the oligometastasis was associated with lower risk of mortality (P=0.03). In contrast, the lack
of complete/partial response (P=0.04) or having a greater oligometastasis size (HR=4.5; P=0.01) was associated with higher risk
of mortality. On multivariate analysis, only the response to the HT retained signiﬁcance (P=0.01).
Conclusions. Hypofractionated image-guided HT is well tolerated and offers adequate local control with low acute morbidity in
patients with extracraneal oligometastatic disease. We found that the response to HT was the only predictor for OS.
http://dx.doi.org/10.1016/j.rpor.2013.03.556
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Introduction. Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very
high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of
technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality
is safe and effective in both early stage primary cancer and oligometastases.
Objective. We present our experience in the treatment of primary and metastatic tumors with SBRT.
Methods. BetweenApril 2012 andFebruary 2013, 22 patientswith 24different locationsunderwent SBRT for primary andmetastatic
tumors using CT and/or PET-CT for diagnosis. Treatment was made using vacuum body ﬁxation and abdominal compression (in
some cases) to reduce intrafractional organ motion. We made three planning CTs in all patients: free breathing, inhalation and
exhalation. Internal target volume (ITV) was delineated based on fusion of three CTs. Planning target volume (PTV) was then
determined by adding additional setup margin to ITV. The locations of the treatments were distributed as follows: 11 primary
lung tumors, 6 lung metastases, 3 adrenal metastasis, 3 lymph node metastasis and 1 vertebral metastases. We have made
different fraction schemes, from 12Gy in 5 fractions (60Gy) until 4Gy in 10 fractions (40Gy).
Results. The acute toxicity has been excellent, appearing only G1 pneumonitis. Assessment of response was performed with CT
and/or PET-CT, with a 80% of local control.
Conclusions. SBRT is a treatment option for many inoperable patients with primary and metastatic tumors and provides a great
beneﬁt, because of its high efﬁciency, with a control of lesions in more than 85% of cases, and excellent clinical tolerance due to
lowest toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.557
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Purpose. We have analyzed our experience with stereotactic body radiation therapy (SBRT) in lung tumors. We have determined
our treatment accuracy using Bodyﬁx® as immobilization system and conebeam CT (CBCT) for image guidance, and the set-up
and treatment times using different planning systems.
Methods and materials. We have studied the patients treated from August 2011 to December 2012. Every patient underwent
4DCT after immobilization with Bodyﬁx®. We contoured the internal target volume (ITV) and we created a planning tar-
get volume (PTV) with a 5mm expansion. A stereotactic RT plan was designed using 7–9 coplanar and noncoplanar ﬁelds,
dynamic arcs or a combination of both of them. Before each fraction a CBCT was made for image guidance. We have mea-
sured the set-up time (total time in treatment room minus beam-on time) and the treatment time (beam-on time), comparing
the length of treatment between different RT plans. We have made CBCT after treatment to study the intrafraction tumor
movements.
Results. Eighteen patients have been treated. Nine patients were treated with ﬁxed ﬁelds, seven with dynamic arcs and two with
a combination of arcs and ﬁelds. Mean times for treatment were 10.4min, 4.3min and 4min, respectively, being arc-therapy
signiﬁcantly faster than ﬁxed ﬁelds treatment (p=0.006). First fraction set-up mean time was 35.7min, signiﬁcantly longer than
overall set-up mean time, that was 27.8min (p<0.05). The mean intrafraction tumor motion was 0.2 cm (0–0.4) in AP, 0.2 cm
(0.1–0.5) in SI and 0.2 cm (0–0.5) in ML direction.
